OBJECTIVES: Biologic therapies are approved for moderate/severe plaque psoriasis.  In trials of newer biologics, many patients achieved complete skin clearance.  This abstract reports interim results from a study examining real-world effectiveness of biologics in psoriasis. METHODS: This prospective observational study includes adults initiating biologic treatment, or switching to a new biologic, for psoriasis in Europe and the US.  Dermatologist evaluation of the Psoriasis Area and Severity Index (PASI) and the patient-reported Psoriasis Symptom Index (PSI] and Dermatology Life Quality Index (DLQI) are collected at baseline, 6 and 12 months after biologic initiation. Endpoints include complete skin clearance (100% improvement in PASI [PASI 100] or PASI=0), PASI 90, PASI 75, PSI and DLQI. Missing data are imputed using the last observation carried-forward.   These interim results include patients who had the opportunity to complete a 6-month assessment. RESULTS: This interim analysis included 126 patients (69.8% male, mean [SD] age 47.3 [14.3] years, mean [SD] psoriasis duration 17.3 [12.9] years).  At baseline, mean (SD) PASI was 14.8 (9.4), and 53.2% patients were biologic-naïve.  At 6-months, 17.5% [95% CI: 11.3%, 25.2%] of patients achieved complete skin clearance; fewer than half (48.0% [39.0%, 57.1%]) achieved a PASI 75, 28.0% [20.3%, 36.7%] achieved a PASI 90, and 17.6% [11.4%, 25.4%] a PASI 100.  In addition, 16.8% of patients had a PSI of 0 and 23.8% a DLQI of 0 (lower scores indicate fewer psoriasis symptoms and better quality of life).  CONCLUSIONS: Fewer than 20% of patients achieved complete skin clearance 6 months after initiating a biologic and less than half achieved a 75% improvement in PASI.  In addition, more than 75% of patients reported some decrement to quality of life and more than 80% reported psoriasis symptoms.  These results suggest that more effective treatments could improve outcomes for many patients with moderate to severe psoriasis.